PL2854814T3 - Modulatory receptorów glukokortykoidowych typu azadekaliny skondensowanej z heteroaryloketonem - Google Patents
Modulatory receptorów glukokortykoidowych typu azadekaliny skondensowanej z heteroaryloketonemInfo
- Publication number
- PL2854814T3 PL2854814T3 PL13793417T PL13793417T PL2854814T3 PL 2854814 T3 PL2854814 T3 PL 2854814T3 PL 13793417 T PL13793417 T PL 13793417T PL 13793417 T PL13793417 T PL 13793417T PL 2854814 T3 PL2854814 T3 PL 2854814T3
- Authority
- PL
- Poland
- Prior art keywords
- heteroaryl
- receptor modulators
- glucocorticoid receptor
- fused azadecalin
- ketone fused
- Prior art date
Links
- 229940117965 Glucocorticoid receptor modulator Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Electroluminescent Light Sources (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261651669P | 2012-05-25 | 2012-05-25 | |
| US201261691083P | 2012-08-20 | 2012-08-20 | |
| US201261715907P | 2012-10-19 | 2012-10-19 | |
| US201361759520P | 2013-02-01 | 2013-02-01 | |
| US201361781629P | 2013-03-14 | 2013-03-14 | |
| EP13793417.0A EP2854814B1 (en) | 2012-05-25 | 2013-05-24 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| PCT/US2013/042732 WO2013177559A2 (en) | 2012-05-25 | 2013-05-24 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2854814T3 true PL2854814T3 (pl) | 2018-07-31 |
Family
ID=49624542
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21154665.0T PL3851107T3 (pl) | 2012-05-25 | 2013-05-24 | Modulatory receptorów glukokortykoidowych typu azadekaliny skondensowanej z heteroaryloketonem |
| PL13793417T PL2854814T3 (pl) | 2012-05-25 | 2013-05-24 | Modulatory receptorów glukokortykoidowych typu azadekaliny skondensowanej z heteroaryloketonem |
| PL19188885T PL3590517T3 (pl) | 2012-05-25 | 2013-05-24 | Modulatory receptorów glukokortykoidowych typu azadekaliny skondensowanej z heteroaryloketonem |
| PL18154256T PL3338781T3 (pl) | 2012-05-25 | 2013-05-24 | Modulatory receptorów glukokortykoidowych typu azadekaliny skondensowanej z heteroaryloketonem |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21154665.0T PL3851107T3 (pl) | 2012-05-25 | 2013-05-24 | Modulatory receptorów glukokortykoidowych typu azadekaliny skondensowanej z heteroaryloketonem |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19188885T PL3590517T3 (pl) | 2012-05-25 | 2013-05-24 | Modulatory receptorów glukokortykoidowych typu azadekaliny skondensowanej z heteroaryloketonem |
| PL18154256T PL3338781T3 (pl) | 2012-05-25 | 2013-05-24 | Modulatory receptorów glukokortykoidowych typu azadekaliny skondensowanej z heteroaryloketonem |
Country Status (23)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| FI3848027T3 (fi) | 2013-11-25 | 2023-05-04 | Corcept Therapeutics Inc | Oktahydrofuusioituja atsadekaliiniglukokortikoidireseptorin modulaattoreita |
| EP3265127B1 (en) * | 2015-03-02 | 2024-02-21 | Corcept Therapeutics, Inc. | Mifepristone and octreotide for use in the treatment of cushing's syndrome in a patient having an adrenocorticotropic hormone (acth)-secreting pancreatic neuroendocrine tumor |
| AU2016243625B2 (en) * | 2015-03-30 | 2020-09-10 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency |
| KR20240014584A (ko) | 2015-05-18 | 2024-02-01 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 쿠싱 증후군을 진단하고 이에 대한 치료를 평가하는 방법 |
| CA2994422A1 (en) | 2015-08-13 | 2017-02-16 | Corcept Therapeutics, Inc. | Method for differentially diagnosing acth-dependent cushing's syndrome |
| MX2018010564A (es) * | 2016-03-01 | 2018-11-09 | Corcept Therapeutics Inc | Uso de moduladores del receptor de glucocorticoides para potenciar inhibidores de puntos de regulacion. |
| US9943505B2 (en) * | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
| UA127409C2 (uk) * | 2017-03-31 | 2023-08-16 | Корцепт Терап'Ютікс, Інк. | Модулятори глюкокортикоїдного рецептора для лікування раку шийки матки |
| CA3065555A1 (en) | 2017-06-20 | 2018-12-27 | Corcept Therapeutics, Inc. | Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators |
| WO2019209693A1 (en) * | 2018-04-23 | 2019-10-31 | Corcept Therapeutics, Inc. | Methods of preparing regioselective n-alkyl triazoles |
| BR112021008719A2 (pt) * | 2018-11-09 | 2021-08-03 | Corcept Therapeutics, Inc. | método para reduzir o tamanho de um tumor pituitário visível em um paciente |
| US11389432B2 (en) | 2018-12-19 | 2022-07-19 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| JP7218438B2 (ja) | 2018-12-19 | 2023-02-06 | コーセプト セラピューティクス， インコーポレイテッド | レラコリラント含有医薬製剤、ヘテロアリールケトン縮合アザデカリン化合物 |
| KR20210107004A (ko) * | 2018-12-20 | 2021-08-31 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 소마토스타틴 수용체 양성 종양의 영상화 및 치료 방법 |
| EP3927345A4 (en) * | 2019-02-22 | 2022-12-21 | Corcept Therapeutics Incorporated | THERAPEUTIC USES OF RELACORILANT, A GLUCOCORTICOID RECEPTOR MODULATOR DERIVED FROM AZADECALIN FUSED TO A HETEROARYL KETONE |
| JP2022552422A (ja) * | 2019-10-16 | 2022-12-15 | コーセプト セラピューティクス， インコーポレイテッド | 選択的グルココルチコイド受容体拮抗物質を用いてがん患者における好中球／リンパ球比を正常化する方法 |
| US11903945B2 (en) | 2019-12-11 | 2024-02-20 | Corcept Therapeutics Incorporated | Methods of treating antipsychotic-induced weight gain with miricorilant |
| CA3162636A1 (en) | 2019-12-21 | 2021-06-24 | Andreas G. MORAITIS | Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome |
| WO2022134033A1 (en) * | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| WO2022166810A1 (zh) * | 2021-02-03 | 2022-08-11 | 江苏恒瑞医药股份有限公司 | 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用 |
| US20240131020A1 (en) * | 2022-10-06 | 2024-04-25 | Corcept Therapeutics Incorporated | Formulations of glucocorticoid receptor modulators |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| GB8828669D0 (en) * | 1988-12-08 | 1989-01-11 | Lilly Industries Ltd | Organic compounds |
| DE602005009687D1 (de) | 2004-03-09 | 2008-10-23 | Corcept Therapeutics Inc | Azadecalinverbindungen mit kondensiertem ring als glucocorticoidrezeptormodulatoren |
| US7640389B2 (en) * | 2006-02-28 | 2009-12-29 | Freescale Semiconductor, Inc. | Non-volatile memory having a multiple block erase mode and method therefor |
| EP1932843A1 (en) * | 2006-12-14 | 2008-06-18 | sanofi-aventis | Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals |
| JP2013536250A (ja) * | 2010-08-27 | 2013-09-19 | コーセプト セラピューティクス， インコーポレイテッド | ピリジル−アミン縮合アザデカリンモジュレーター |
-
2013
- 2013-05-24 ES ES18154256T patent/ES2753816T3/es active Active
- 2013-05-24 EP EP22193438.3A patent/EP4119561A1/en active Pending
- 2013-05-24 PT PT137934170T patent/PT2854814T/pt unknown
- 2013-05-24 RU RU2014152625A patent/RU2639867C2/ru active
- 2013-05-24 PL PL21154665.0T patent/PL3851107T3/pl unknown
- 2013-05-24 ES ES21154665T patent/ES2930298T3/es active Active
- 2013-05-24 PT PT181542564T patent/PT3338781T/pt unknown
- 2013-05-24 EP EP13793417.0A patent/EP2854814B1/en active Active
- 2013-05-24 KR KR1020147036405A patent/KR102062640B1/ko active IP Right Grant
- 2013-05-24 SG SG11201407682TA patent/SG11201407682TA/en unknown
- 2013-05-24 ES ES13793417.0T patent/ES2665338T3/es active Active
- 2013-05-24 DK DK13793417.0T patent/DK2854814T3/en active
- 2013-05-24 PL PL13793417T patent/PL2854814T3/pl unknown
- 2013-05-24 PT PT191888858T patent/PT3590517T/pt unknown
- 2013-05-24 AU AU2013266110A patent/AU2013266110C1/en active Active
- 2013-05-24 DK DK18154256T patent/DK3338781T3/da active
- 2013-05-24 MX MX2014014239A patent/MX365423B/es active IP Right Grant
- 2013-05-24 EP EP21154665.0A patent/EP3851107B1/en active Active
- 2013-05-24 WO PCT/US2013/042732 patent/WO2013177559A2/en active Application Filing
- 2013-05-24 EP EP18154256.4A patent/EP3338781B1/en active Active
- 2013-05-24 PT PT211546650T patent/PT3851107T/pt unknown
- 2013-05-24 EP EP19188885.8A patent/EP3590517B1/en active Active
- 2013-05-24 JP JP2015514233A patent/JP6172871B2/ja active Active
- 2013-05-24 PL PL19188885T patent/PL3590517T3/pl unknown
- 2013-05-24 NZ NZ701469A patent/NZ701469A/en unknown
- 2013-05-24 DK DK21154665.0T patent/DK3851107T3/da active
- 2013-05-24 CA CA2872260A patent/CA2872260C/en active Active
- 2013-05-24 DK DK19188885.8T patent/DK3590517T3/da active
- 2013-05-24 BR BR112014028857-7A patent/BR112014028857B1/pt active IP Right Grant
- 2013-05-24 ES ES19188885T patent/ES2873949T3/es active Active
- 2013-05-24 CN CN201380039218.1A patent/CN104619328B/zh active Active
- 2013-05-24 MY MYPI2014003289A patent/MY172739A/en unknown
- 2013-05-24 PL PL18154256T patent/PL3338781T3/pl unknown
- 2013-05-24 PE PE2014002054A patent/PE20150352A1/es active IP Right Grant
-
2014
- 2014-11-10 ZA ZA2014/08182A patent/ZA201408182B/en unknown
- 2014-11-19 PH PH12014502584A patent/PH12014502584A1/en unknown
- 2014-11-21 CL CL2014003173A patent/CL2014003173A1/es unknown
- 2014-11-23 IL IL235868A patent/IL235868A/en active IP Right Grant
-
2015
- 2015-09-29 HK HK15109587.3A patent/HK1208818A1/xx unknown
-
2018
- 2018-07-23 HK HK18109510.2A patent/HK1250014B/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1250014B (zh) | 雜芳基-酮稠合的氮萘烷糖皮質激素受體調節劑 | |
| ZA201604026B (en) | Octahydro fused azadecalin glucocorticoid receptor modulators | |
| EP2609097A4 (en) | AZADECALINE PYRIDYL-AMINE MODULATORS | |
| HK1206332A1 (en) | Liver receptor modulators | |
| HK1206333A1 (en) | Liver receptor modulators | |
| HK1223353A1 (zh) | 受體調節劑 | |
| HK1209744A1 (en) | Novel selective androgen receptor modulators | |
| IL235557A0 (en) | Modulators of 17 gpr receptors | |
| EP2935284A4 (en) | HETEROCYCLIC MODULATORS OF HORMONE NUCLEAR RECEPTORS | |
| HUE049728T2 (hu) | Benzofurán-2-szulfonamid származékok, mint kemokin receptor modulátorok | |
| EP2892527A4 (en) | HETEROCYCLIC MODULATORS OF NUCLEAR HORMONAL RECEPTORS | |
| EP2922539A4 (en) | SUBSTITUTED ISOQUINOLINES USEFUL AS MODULATORS OF THE CRTH2 RECEPTOR |